First Time Loading...

E-Therapeutics PLC
LSE:ETX

Watchlist Manager
E-Therapeutics PLC Logo
E-Therapeutics PLC
LSE:ETX
Watchlist
Price: 9.4 GBX -3.59% Market Closed
Updated: May 4, 2024
Section:
 

Wall Street
Price Targets

ETX Price Targets Summary
E-Therapeutics PLC

Wall Street analysts forecast ETX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ETX is 10 GBX .

ETX Lowest Forecast
Wall Street Target
Not Available
ETX Average Forecast
Wall Street Target
10 GBX
6% Upside
ETX Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
10 GBX
6% Upside
Highest
Price Target
Not Available
E-Therapeutics PLC Competitors:
Price Targets
068270
Celltrion Inc
29% Upside
KOD
Kodiak Sciences Inc
15% Upside
BPMC
Blueprint Medicines Corp
7% Downside
IONS
Ionis Pharmaceuticals Inc
35% Upside
068270
Celltrion Inc
29% Upside
KOD
Kodiak Sciences Inc
15% Upside
BPMC
Blueprint Medicines Corp
7% Downside
IONS
Ionis Pharmaceuticals Inc
35% Upside
IMMU
Mendus AB (publ)
169% Upside
ALKS
Alkermes Plc
51% Upside
FHTX
Foghorn Therapeutics Inc.
134% Upside
300896
Imeik Technology Development Co Ltd
64% Upside

Revenue
Forecast

Revenue Estimate
E-Therapeutics PLC

The compound annual growth rate of E-Therapeutics PLC's revenue for the next 1 year is 8%.

N/A
Past Growth
8%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
E-Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
E-Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-58%
Average Miss
What are analyst estimates?

See Also

Summary
ETX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ETX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ETX stock valuation using valuation multiples.
Wall Street Estimates
ETX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ETX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ETX's stock price target?
Price Target
10 GBX

According to Wall Street analysts, the average 1-year price target for ETX is 10 GBX .

What is E-Therapeutics PLC's Revenue forecast?
Projected CAGR
8%

The compound annual growth rate of E-Therapeutics PLC's revenue for the next 1 year is 8%.

ALPHA SPREAD
Join more than 134,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.